Effects of Exenatide on Measures of β-Cell Function After 3 Years in Metformin-Treated Patients With Type 2 Diabetes
Open accessThe DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: We previously showed that exenatide (EXE) enhanced insulin secretion after 1 year of treatment, relative to insulin glargine (GLAR), with a similar glucose-lowering action. These effects were not sustained after a 4-week off-drug period. This article reports the results after additional 2 years of exposure. RESEARCH DESIGN AND METHODS: Sixty-nine metformin-treated patients with type 2 diabetes were randomized to EXE or GLAR. Forty-six patients entered the 2-year extension study in which they continued their allocated therapy. Thirty-six completed (EXE: n = 16; GLAR: n = 20) the 3-year exposure period. Insulin sensitivity (M value) and β-cell function were measured by euglycemic hyperinsulinemic clamp followed by hyperglycemic clamp with arginine stimulation at pretreatment (week 52) and 4 weeks after discontinuation of study medication (week 56 and week 172). First-phase glucose stimulated C-peptide secretion was adjusted for M value and calculated as the disposition index (DI). RESULTS: At 3 years, EXE and GLAR resulted in similar levels of glycemic control: 6.6 ± 0.2% and 6.9 ± 0.2%, respectively (P = 0.186). EXE compared with GLAR significantly reduced body weight (−7.9 ± 1.8 kg; P < 0.001). After the 4-week off-drug period, EXE increased the M value by 39% (P = 0.006) while GLAR had no effect (P = 0.647). Following the 4-week off-drug period, the DI, compared with pretreatment, increased with EXE, but decreased with GLAR (1.43 ± 0.78 and −0.99 ± 0.65, respectively; P = 0.028). CONCLUSIONS: EXE and GLAR sustained HbA1c over the 3-year treatment period, while EXE reduced body weight and GLAR increased body weight. Following the 3-year treatment with EXE, the DI was sustained after a 4-week off-drug period. These findings suggest a beneficial effect on β-cell health.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures



Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“none of these agents have produced a meaningful, persistent change following therapy withdrawal ( 71 , 73 ).”
From β-Cell Failure in Type 2 Diabetes: Postulated Mechanisms and Prospects for Prevention and Treatment (2014) · cites this paper as [73]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“The long-term effects of GLP-1RA go beyond the improvement in glucose metabolism and weight loss [34,35,36,37,38,39] and it is now established their beneficial effects of hepatic metabolism and histology.”
From Gut-pancreas-liver Axis as a target for treatment of NAFLD/NASH (2020) · cites this paper as [35]
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Further analyses from TODAY show that in youth with type 2 diabetes dyslipidaemia162 and hypertension163 are common and worsen over time.”
From Pathophysiology and treatment of type 2 diabetes: perspectives on the past, present, and future (2014) · cites this paper as [162]
Experimental — accuracy not yet measuredIn the citing paper
“In one study of exenatide,25 patients underwent two treatment phases—52 weeks followed by 104 weeks—with a 12-week off-treatment period after each phase.”
From Trajectory of weight regain after cessation of GLP-1 receptor agonists: a systematic review and nonlinear meta-regression (2026) · cites this paper as [25]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Glucose clamp technique: a method for quantifying insulin secretion and resistance.
DeFronzo, R. A., Tobin, J. D., & Andres, R. (1979) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.1979.237.3.e214 · Cited by 7,425
Drucker, D. J., & Nauck, M. A. (2006) · The Lancet · doi:10.1016/s0140-6736(06)69705-5 · Cited by 3,896
Nathan, D. M., Buse, J. B., Davidson, M. B., Ferrannini, E., Holman, R. R., Sherwin, R., & Zinman, B. (2009) · Diabetes Care · doi:10.2337/dc08-9025 · Cited by 3,834
Biology of Incretins: GLP-1 and GIP
Baggio, L. L., & Drucker, D. J. (2007) · Gastroenterology · doi:10.1053/j.gastro.2007.03.054 · Cited by 3,639 · cited 1×
“Although human data are not available, exposure to GLP-1 and GLP-1RA in the preclinical setting results in b-cell proliferation, islet neogenesis, and inhibition of b-cell apoptosis in (human) cell lines, primary rodent islets, and in vivo in different rodent species (13).”
BackgroundKahn, S. E. (2003) · Diabetologia · doi:10.1007/s00125-002-1009-0 · Cited by 2,166
U.K. Prospective Diabetes Study Group (1995) · Diabetes · doi:10.2337/diab.44.11.1249 · Cited by 1,923
Kahn, S. E., Prigeon, R. L., McCulloch, D. K., Boyko, E. J., Bergman, R. N., Schwartz, M. W., Neifing, J. L., Ward, W. K., Beard, J. C., & Palmer, J. P. (1993) · Diabetes · doi:10.2337/diab.42.11.1663 · Cited by 1,405 · cited 2×
“The disposition index (DI), a measure of b-cell function and adjusted for insulin sensitivity, was calculated bymultiplying the firstphase incremental C-peptide secretion with the M value (AIRgluc*M) (12).”
BackgroundMethodZander, M., Madsbad, S., Madsen, J. L., & Holst, J. J. (2002) · The Lancet · doi:10.1016/s0140-6736(02)07952-7 · Cited by 1,297 · cited 1×
“(21) was the first to report a beneficial effect of continuous GLP-1 infusion on clamp-measured b-cell function as well as insulin sensitivity in the presence of concomitant weight loss of 1.”
BackgroundCauter, E. V., Mestrez, F., Sturis, J., & Polonsky, K. S. (1992) · Diabetes · doi:10.2337/diab.41.3.368 · Cited by 890
DeFronzo, R. A. (2010) · Diabetologia · doi:10.1007/s00125-010-1684-1 · Cited by 879
Effect of ramipril on the incidence of diabetes
(2006) · New England Journal of Medicine · doi:10.1056/nejmoa065061 · Cited by 737
β-Cell Failure in Diabetes and Preservation by Clinical Treatment
Wajchenberg, B. L. (2007) · Endocrine Reviews · doi:10.1210/10.1210/er.2006-0038 · Cited by 714
Cauter, E. V., Mestrez, F., Sturis, J., et al. (1992) · Diabetes · doi:10.2337/diabetes.41.3.368 · Cited by 643
Diminished B cell secretory capacity in patients with noninsulin-dependent diabetes mellitus
Ward, W. K., Bolgiano, D. C., McKnight, B., Halter, J. B., & Porte, D. (1984) · Journal of Clinical Investigation · doi:10.1172/jci111542 · Cited by 483 · cited 1×
“Arginine was administered at t = 260 min during the hyperglycemic clamp to estimate maximum insulin secretory capacity at a steady-state glucose concentration of 15 mmol/L (11).”
MethodEffect of nateglinide on the incidence of diabetes and cardiovascular events
(2010) · New England Journal of Medicine · doi:10.1056/nejmoa1001122 · Cited by 477
Bunck, M. C., Diamant, M., Cornér, A., Eliasson, B., Malloy, J. L., Shaginian, R. M., Deng, W., Kendall, D. M., Taskinen, M.-R., Smith, U., et al. (2009) · Diabetes Care · doi:10.2337/dc08-1797 · Cited by 388 · cited 6×
“We previously showed that EXE, as compared with insulin glargine (GLAR), improved pancreatic b-cell secretory function against a background of similar glycemic control (7).”
BackgroundMethodResultInfluentialSelf-citationVilsbøll, T., Brock, B., Perrild, H., Levin, K., Lervang, H. ‐., Kølendorf, K., Krarup, T., Schmitz, O., Zdravkovic, M., Le‐Thi, T., et al. (2008) · Diabetic Medicine · doi:10.1111/j.1464-5491.2007.02333.x · Cited by 213
Fatty acids and glucolipotoxicity in the pathogenesis of Type 2 diabetes
Cnop, M. (2008) · Biochemical Society Transactions · doi:10.1042/bst0360348 · Cited by 208
Bunck, M. C., Diamant, M., Eliasson, B., Cornér, A., Shaginian, R. M., Heine, R. J., Taskinen, M.-R., Yki-Järvinen, H., & Smith, U. (2010) · Diabetes Care · doi:10.2337/dc09-2361 · Cited by 161 · cited 1×
“We recently demonstrated that EXE predominantly reduces trunkal fat mass, whereas lean body mass was not affected (20).”
BackgroundSelf-citationInitiate Insulin by Aggressive Titration and Education (INITIATE)
Yki-Järvinen, H., Juurinen, L., Alvarsson, M., Bystedt, T., Caldwell, I., Davies, M., Lahdenperä, S., Nijpels, G., & Vähätalo, M. (2007) · Diabetes Care · doi:10.2337/dc06-1357 · Cited by 139 · cited 1×
“6 mmol/L) according to a prespecified treat-to-target algorithm (8).”
MethodDeFronzo, R. A., Triplitt, C., Qu, Y., Lewis, M. S., Maggs, D., & Glass, L. C. (2010) · Diabetes Care · doi:10.2337/dc09-1521 · Cited by 104 · cited 2×
“Subsequent clinical studies using the euglycemic hyperinsulinemic clamp, insulin-modified frequently sampled intravenous glucose tolerance test, or homeostasis model assessment of insulin resistance do not provide a clear view of the effects of GLP-1RA on insulin sensitivity and suggest that such an effect may be seco…”
BackgroundResultManagement of hyperglycaemia in type 2 diabetes: the end of recurrent failure?
Heine, R. J., Diamant, M., Mbanya, J.-C., & Nathan, D. M. (2006) · BMJ · doi:10.1136/bmj.39022.462546.80 · Cited by 100
Self-citationExenatide efficacy and safety: a systematic review
Norris, S. L., Lee, N., Thakurta, S., & Chan, B. K. S. (2009) · Diabetic Medicine · doi:10.1111/j.1464-5491.2009.02790.x · Cited by 88
Gedulin, B. R., Smith, P., Prickett, K. S., Tryon, M. S., Barnhill, S. D., Reynolds, J., Nielsen, L. L., Parkes, D. G., & Young, A. A. (2005) · Diabetologia · doi:10.1007/s00125-005-1795-2 · Cited by 82
Diet-Induced Weight Loss Is Associated with an Improvement in β-Cell Function in Older Men
Utzschneider, K. M., Carr, D. B., Barsness, S. M., Kahn, S. E., & Schwartz, R. S. (2004) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2003-031827 · Cited by 73 · cited 1×
“Body weight reduction per se has been shown to improve b-cell function in subjects with and without type 2 diabetes (18,19).”
BackgroundWeight Loss Therapy Improves Pancreatic Endocrine Function in Obese Older Adults
Villareal, D. T., Banks, M. R., Patterson, B. W., Polonsky, K. S., & Klein, S. (2008) · Obesity · doi:10.1038/oby.2008.226 · Cited by 63
Cited by
DeFronzo, R. A., Ferrannini, E., Groop, L., Henry, R. R., Herman, W. H., Holst, J. J., Hu, F. B., Kahn, C. R., Raz, I., Shulman, G. I., et al. (2015) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2015.19 · Cited by 2,611
Mechanisms of Action and Therapeutic Application of Glucagon-like Peptide-1
Drucker, D. J. (2018) · Cell Metabolism · doi:10.1016/j.cmet.2018.03.001 · Cited by 2,170
Pathophysiology and treatment of type 2 diabetes: perspectives on the past, present, and future
Kahn, S. E., Cooper, M. E., & Del Prato, S. (2014) · The Lancet · doi:10.1016/s0140-6736(13)62154-6 · Cited by 1,743
Pharmacology, physiology, and mechanisms of incretin hormone action.
Campbell, J. E., & Drucker, D. J. (2013) · Cell Metabolism · doi:10.1016/j.cmet.2013.04.008 · Cited by 1,500
GLP-1 receptor agonists for individualized treatment of type 2 diabetes mellitus
Meier, J. J. (2012) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2012.140 · Cited by 1,311
Metadata
- Authors
- Bunck, M. C., Cornér, A., Eliasson, B., Heine, R. J., Shaginian, R. M., Taskinen, M.-R., Smith, U., Yki-Järvinen, H., & Diamant, M.
- Affiliations
- Amsterdam UMC Location Vrije Universiteit Amsterdam (NL)
- Helsinki University Hospital (FI)
- Lundberg Laboratory for Diabetes Research, Sahlgrenska University Hospital, Goteborg, Sweden
- Eli Lilly (United States) (US)
- Eli Lilly (Netherlands) (NL)
- Sahlgrenska University Hospital (SE)
- Department of Medicine, Helsinki University Central Hospital, Helsinki, Finland
- Diabetes Center, Department of Internal Medicine, VU University Medical Center, Amsterdam, the Netherlands
- Corresponding author
- Bunck, Mathijs C.
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2011-08-19
- Volume
- 34
- Issue
- 9
- Pages
- 2041-2047
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- PMC
- PMC3161303
- OpenAlex
- W2029228033
- Cited by
- 240
- References
- 25
- Citations by year
- 2026: 2 · 2025: 7 · 2024: 5 · 2023: 10 · 2022: 11 · 2021: 11 · 2020: 13 · 2019: 12 · 2018: 20 · 2017: 29 · 2016: 24 · 2015: 23 · 2014: 27 · 2013: 28 · 2012: 12
- FWCI
- 19.13
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Diabetes Care (publishedVersion, cc-by-nc-nd)
- Europe PMC (PubMed Central) (publishedVersion, cc-by-nc-nd)
- PubMed Central (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- Pure Amsterdam UMC (publishedVersion)
- Amsterdam UMC (VU Amsterdam) - Institutional Repository (publishedVersion)
- Data Archiving and Networked Services (DANS) (submittedVersion, other-oa)
- Data Archiving and Networked Services (DANS) (submittedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Pancreatic function and diabetes
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Keywords
- exenatide, insulin glargine, type 2 diabetes, metformin, beta-cell function, insulin secretion, insulin sensitivity, disposition index, glycemic control, body weight, long-term treatment, GLP-1 receptor agonists
- MeSH terms
- Insulin Glargine, Exenatide, Adult, Aged, Blood Glucose, Body Weight, C-Peptide, Diabetes Mellitus, Type 2, Female, Glycated Hemoglobin, Humans, Hypoglycemic Agents, Male, Metformin, Middle Aged, Peptides, Venoms, Insulin, Long-Acting, Insulin-Secreting Cells
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.